Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 19 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 MkPRR5l1d3SxeHnjbZR6KEG|c3H5 NHTsc5cx6oDVMU[wxsDPxE1? M4jifFQ5yqCq M13ud2lEPTB;NT64xsDDucLiMD61JO69VQ>? M3vvZlI3PDd2Nkmz
CaES-17 M2DafmN6fG:2b4jpZ4l1gSCDc4PhfS=> MVew5qCUOTZywrFOwG0> NVS5cnJDPDkEoHi= NFfQe|BKSzVyPUWuOeKhyrIEoECuNkDPxE1? MoTyNlY1PzR4OUO=
SW480 NVXodppTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDBWI01QCCqwrC= MnXuTWM2OD1zLki3JO69VQ>? NGf3NnAzPjJ4OUe1PS=>
HCT116 NYnyZZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDBOFghcMLi NFH2dFFKSzVyPUGxMlg3KM7:TR?= M4q0bVI3OjZ7N{W5
LoVo Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHMdlBDPDhiaNMg MXXJR|UxRTl2LkizJO69VQ>? MWmyOlI3QTd3OR?=
SK-BR-3 NGjp[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTNzLkCgxtEhOC5zIN88US=> M1;DWVI3OjFzNUmx
MCF-7 M4Hrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HMemlEPTB;MUWuOEDDuSByLkOg{txO NYXDPWVlOjZ{MUG1PVE>
MDA-MB-231 M4\SdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ|LkGgxtEhOC5zIN88US=> NF76ZnEzPjJzMUW5NS=>
HCT116 p53+/+ MoXISpVv[3Srb36gRZN{[Xl? MnzENU82KM7:TR?= Mkj6NlQwPDhiaB?= M2XzXolv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= M2rTd|I3OjB6NUKz
LoVo  MmfRSpVv[3Srb36gRZN{[Xl? M{e0blEwPSEQvF2= MnHRNlQwPDhiaB?= NIH2[4FqdmS3Y3XzJJRz[W6|Y4LpdJRqd26jbDDy[ZBz\XO|aX;uJI9nKESXVD3O NX;lbZB1OjZ{MEi1NlM>
SNU-398 M33pXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTZwNdMgxtHDqDFwMTFOwG0> M1TjPFI3OTZyNEK5
Hep-G2 MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITIdG1KSzVyPUGzMlHDqMLzwrCxMlYh|ryP NH3IO5UzPjF4MESyPS=>
SNU-475 M2jsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:zcGlEPTExvK6zNEDPxE1? NFrKTGMzPjF4MESyPS=>
SNU-387 MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi0VZRGUUN3ME2yOeKhyrIEoEKuO{DPxE1? M3K5U|I3OTZyNEK5
HT29 NFX6NIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn5U3c2UUN3ME2wMlg5yqEEsdMgNE4zKM7:TR?= MoHmNlYyPDh3OU[=
HCT116 M2DqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLmUJNGUUN3ME2wMlQyyqEEsdMgNE4xOiEQvF2= MWWyOlE1QDV7Nh?=
PA-1 MojuR4VtdCCYaXHibYxqfHliQYPzZZk> MWCwMVIxKM7:TR?= MX6yOE81QCCq M3TLUIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M4TKNFI3OTN6Nkex
OVCAR-5 MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVzaTVNkOC14MDFOwG0> MWWyOE81QC95MjDo M2PKeolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NWT2ZoFkOjZzM{i2O|E>
SK-OV-3 NVv5eIQyS2WubDDWbYFjcWyrdImgRZN{[Xl? Mom3NE0yODBizszN MkW3NlQwPDhxN{KgbC=> MmTObY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MYOyOlE{QDZ5MR?=
PA-1 NVjoZ2M2TnWwY4Tpc44hSXO|YYm= NXv1cFZDOTBizszNxsA> M2rybVI1cA>? NYrwbZRlfHKrZ3fldoV{KHSqZTDwdo9lfWO2aX;uJI9nKHS7cHWgTUBKTk6|IHHu[EBkcGWvb3vpcoV{ MViyOlE{QDZ5MR?=
OVCAR-5 MoruSpVv[3Srb36gRZN{[Xl? M1L6TVMxKM7:TR?= M2PURVQ5cA>? NXPXbXRMfHKrZ3fldoV{KHSqZTDwdo9lfWO2aX;uJI9nKHS7cHWgTUBKTk6|IHHu[EBkcGWvb3vpcoV{ M3HtWVI3OTN6Nkex
SK-OV-3 NV7oPIY4TnWwY4Tpc44hSXO|YYm= NXf0e3ZvPTBizszN MlLSPVYhcA>? NIr2XXZ1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> NXzHbINwOjZzM{i2O|E>
PA-1 NYm3Z2FNTnWwY4Tpc44hSXO|YYm= NE\wcYQyOCEQvF5CpC=> NVm1boN5PDiq NGDMXpp2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? NVe2dopzOjZzM{i2O|E>
OVCAR-5 NHu4coZHfW6ldHnvckBCe3OjeR?= Mkn3N|Ah|ryP M1TPW|Q5cA>? NXq5WXN1fXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| M1i3b|I3OTN6Nkex
SK-OV-3 M3LXO2Z2dmO2aX;uJGF{e2G7 NXjEWGpOPTBizszN NH\kN206PiCq M1vNSJVxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>? NGP0OIszPjF|OE[3NS=>
PA-1 M4XqOGZ2dmO2aX;uJGF{e2G7 NGnZT3MyOCEQvF5CpC=> NUXP[JVZOjSq NHnKbY9xem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> MnLvNlYyOzh4N{G=
OVCAR-5 M2nDfGZ2dmO2aX;uJGF{e2G7 M{fXZVIxKM7:TdMg MoDUNlRp M4jjdJBzd22xdHXzJJNmdnOrdHn2bZR6KG:oIH;2ZZJq[W5iY3HyZ4lvd22jIITvJG5MKGOnbHytcYVlcWG2ZXSgZ5l1d2y7c3nz MmPpNlYyOzh4N{G=
SK-OV-3 NUHzTZI2TnWwY4Tpc44hSXO|YYm= MoDTOVAh|ryPwrC= MkDmOFghcMLi M3m5cpBzd22xdHXzJJNmdnOrdHn2bZR6KG:oIH;2ZZJq[W5iY3HyZ4lvd22jIITvJG5MKGOnbHytcYVlcWG2ZXSgZ5l1d2y7c3nz NV35fWFyOjZzM{i2O|E>
CT26  MXzGeY5kfGmxbjDBd5NigQ>? NEPaVWM1KG2P M37pS|Q5KGkEoB?= Mn;6bY5lfWOnczDheZRweGijZ4m= M1nRcFI3OTN5MEGy
CT26  NHf4bGZHfW6ldHnvckBCe3OjeR?= NWqycWh1PCCvTR?= NX3jNYs1PDhiaNMg MUPpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Yx{KG:oIHH1eI9xcGGpeT3y[YxifGWmIIDyc5RmcW6|LDDzeYNpKGG|IFzDN{1KUSxiQnXjcIlvOSCjbnSgRXRIPQ>? MX6yOlE{PzBzMh?=
CT26  NInldXFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmPuOEBuVQ>? MWq0PEBpyqB? NFO3RZZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeI8hPTNwMjW= M4XDeFI3OTN5MEGy
BE NImyfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTNwM{Og{txO MYKyOlAzOzB6NR?=
Colo205 NXXwUHFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPK[IdkUUN3ME2zMlM{KM7:TR?= Mn;RNlYxOjNyOEW=
DLD1 MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1qxNGlEPTB;Mj6wNUDPxE1? M3v5eFI3ODJ|MEi1
HT29 NYTxcFFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJwNkmg{txO Ml;oNlYxOjNyOEW=
HCT15 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fwcWlEPTB;MT60N{DPxE1? NFznWHMzPjB{M{C4OS=>
HCT116 M1;wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i0SWlEPTB;MT6wOEDPxE1? NIG5N5IzPjB{M{C4OS=>
HCT116p53- MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXlVIZiUUN3ME2xMlA5KM7:TR?= NYDZZ3B6OjZyMkOwPFU>
KM12 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOyTWM2OD12LkO3JO69VQ>? M4DSOVI3ODJ|MEi1
LoVo NUHNZ5VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jyZ2lEPTB;MT6yJO69VQ>? NV;1UYdYOjZyMkOwPFU>
RKO NGXPSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jNTWlEPTB;MT6yN{DPxE1? NH3HTlgzPjB{M{C4OS=>
SW480 NG\DO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrUfW9mUUN3ME2yMlg3KM7:TR?= MkDxNlYxOjNyOEW=
SW620 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3tPZNKSzVyPUOuOlgh|ryP M1qzWFI3ODJ|MEi1
MC38 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6yfZNKSzVyPUKzJO69VSEEsTCy NVSwNXAzOjZyMESwPFQ>
HT29 NVTvSm1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPEZm9EUUN3ME22N{DPxE1iwsGgNVg> MmG0NlYxODRyOES=
DLD-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jKZWlEPTB;M{KuNkDPxE1? NVHGWphXOjZyMEOwPFU>
HT-29 M3fNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnoW5RKSzVyPUO1MlYh|ryP Mn\wNlYxODNyOEW=
SiHa M3flVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwODFCtUAxNjFizszN MYeyOVgxOTByNx?=
S3 NHm5eVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvJVpZ4UUN3ME21N{42KMLzIEGuOUDPxE1? MYiyOVgxOTByNx?=
AGS Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXVTWM2OD1zMD62JO69VQ>? M1jlOFI2Pzh7MEW3
MKN-45 NGDpfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF2LkCg{txO NXzoRlAyOjV5OEmwOVc>
TMK-1 M4T5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrGTWM2OD1{Mj62JO69VQ>? NEjRO3QzPTd6OUC1Oy=>
SCM-1 NVTPUFdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF5LkWg{txO MljRNlU4QDlyNUe=
HCT-15 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\1XG5XUUN3ME24MlY1KM7:TR?= NIfsc5YzPTd4MUS3PS=>
DiFi M3n2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFyLkm1JO69VQ>? MYmyOVc3OTR5OR?=
DLD-1 NXK5U2s2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vQRmlEPTB;OD62OUDPxE1? NGjPOnozPTd4MUS3PS=>
COLO-320DM MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlK5TWM2OD13LkO4JO69VQ>? MYeyOVc3OTR5OR?=
SNU-175 M3y2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrI[I1KSzVyPUGuOVEh|ryP Mk\SNlU4PjF2N{m=
HT-29 M1TsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDiTWM2OD13LkKyJO69VQ>? MVeyOVc3OTR5OR?=
SW620 NFjwWlNHfW6ldHnvckBCe3OjeR?= MWSxNQKBkcL3Zz;tcC=> M4P6R|I16oDLaB?= NU\aPVBzcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= M2\JdVI2PzR7NEKw
SW480 Ml3MSpVv[3Srb36gRZN{[Xl? M2rrWFEx6oDLwsXnM41t MorWNlTjiImq NFO4VGtqdmO{ZXHz[ZMhVEN|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w NWG3[FRXOjV5NEm0NlA>
SW620 MlXPSpVv[3Srb36gRZN{[Xl? NEnYVIoyOOLCidM1[{9udA>? M4XObVI16oDLaB?= MlfS[Y5p[W6lZYOgZ4VtdHWuYYKgZZV1d3CqYXfpZ{BndHW6 MlfwNlU4PDl2MkC=
SW480 NEftdJpHfW6ldHnvckBCe3OjeR?= NGDvTpYyOOLCidM1[{9udA>? M2nLWlI16oDLaB?= MVzlcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? MWmyOVc1QTR{MB?=
A549 NFXL[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[2TpNKSzVyPUWuPEDDuSByLk[g{txO M1[ySlI2PjJ3MkSz
A549/CDDP MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILQOWtKSzVyPUG4MlYhyrFiMT6yJO69VQ>? NFnBW4EzPTZ{NUK0Ny=>
Panc-1 M12wS2NmdGxiVnnhZoltcXS7IFHzd4F6 MkLQNlUwPTBizszN NYP4dXlJOjRxNEigbC=> M{TDXolvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NHXvNlAzPTR2NEmxOC=>
MIAPaCa-2 Ml\oR4VtdCCYaXHibYxqfHliQYPzZZk> M2rXOFI2NzVyIN88US=> MkDtNlQwPDhiaB?= M1LEc4lvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NWjzU4ptOjV2NES5NVQ>
SW1990 M3vFWGNmdGxiVnnhZoltcXS7IFHzd4F6 NVzWV2o6OjVxNUCg{txO MoK3NlQwPDhiaB?= MXHpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> NUjIPJhROjV2NES5NVQ>
HPDE MoDKR4VtdCCYaXHibYxqfHliQYPzZZk> M3TJNVI2NzVyIN88US=> NWjPTGhSOjRxNEigbC=> MmjFbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MYKyOVQ1PDlzNB?=
Panc-1 M2XP[mFxd3C2b4Ppd{BCe3OjeR?= MViyOgKBkcL3TR?= MmSzNlQhcA>? NYnmTVNVcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= NH;qN4MzPTR2NEmxOC=>
MIAPaCa-2 MkjuRZBweHSxc3nzJGF{e2G7 MUiyOgKBkcL3TR?= M1nveVI1KGh? Mnz1bY5lfWOnczDhdI9xfG:|aYOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? M1iyfFI2PDR2OUG0
Panc-1 NXX6dmY5TnWwY4Tpc44hSXO|YYm= MmjyNlXjiIoEtV2= M1jte|I1NzR6IHi= M{jLdYlv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg NIjhTFkzPTR2NEmxOC=>
MIAPaCa-2 NUDpXnZETnWwY4Tpc44hSXO|YYm= MXSyOgKBkcL3TR?= MXSyOE81QCCq M1X3Solv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg NEXldGozPTR2NEmxOC=>
SW480 NW\NeFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M324[lczKGkEoB?= M37hd2lEPTB;MUCuO:KyOi5{NjFCuYcwdUx? NFv1OnczPTN4ME[zNS=>
HCT116  NUP6coI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvvO|IhcMLi NFXnZXBKSzVyPU[uNlPDuTBwN{WgxtVoN22O NX:4d4NMOjV|NkC2N|E>
COC1 NVnuXZd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofVTWM2OD12Nj6yNOKhyrIEoEOuNVQh|ryP M1XQWlI2OzB5NES4
SGC7901 M3PUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfoUmhnUUN3ME2yNU44O8LiwsJCpFMvODhizszN NIf0cHQzPTNyN{S0PC=>
A549 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELOeWhKSzVyPUWxMlA5yqEEsdMgNVAvQTZizszN Mn3sNlU{ODd2NEi=
HepG2 NFmy[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTLfVZ5UUN3ME2xOE4zPMLiwsJCpFEvQDJizszN MnPTNlU{ODd2NEi=
MCF-7 NXrLdJE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;IdVFKSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2= NEiyb3AzPTNyN{S0PC=>
HCT-116 M2X2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu4TWM2OD14LkK0xsDDucLiMj65O{DPxE1? MVOyOVMxPzR2OB?=
HT-29 NHLEco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\LWItKSzVyPkWwJO69VQ>? NIXEdmozPTNyN{S0PC=>
HEK293 M1nENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfoNWZKSzVyPUiuPFLDqMLzwrC1MlU6KM7:TR?= Mn31NlU{ODd2NEi=
HUVEC MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonLTWM2OD1zMT6zNOKhyrIEoEGuNFIh|ryP Ml;oNlU{ODd2NEi=
SW480 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjNPWtiOcLizszN MYGwMVczKGh? NIjQOVZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NG\z[WQzPDl7N{S1NS=>
HT-29 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOxxsDPxE1? MmPPNE04OiCq MoLobY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NF7kbngzPDl7N{S1NS=>
HCT116 NFrMUlVHfW6ldHnvckBCe3OjeR?= MVyyM|UhyrWP M2\yclI1NzR6IHi= NXvYflVIe3WycILld5NmeyC|dYL2bZZqdiCvUl7BJIV5eHKnc4Ppc44> NVzHcHFjOjR5NkG0NVE>
SW480  M2PaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSxN2E1QCCqwrC= M3\OTGlEPTB;MkCuPEB2\y:vTB?= MWqyOFczODZ5NR?=
SW620 MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PNfVExNTdyIH3nM2w> NUXwe4xEOjRxNEivO|IhcA>? NGX6[3NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NVLp[5ZJOjR4NE[zNFU>
Caco2  MYDGeY5kfGmxbjDBd5NigQ>? NWPXVVByOzEEoN88US=> MVyyOEBp M1OyRWROW09? MoXZbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDIU{0yNCCDS2KxR{wh[W6mIF7RU|E> NWnRfVNGOjR3NU[0NVU>
Caco2  NV7Pdnd6TnWwY4Tpc44hSXO|YYm= NELYVos{NzFyL{OwJO69VQ>? NH2zboUyPiCq MWDEUXNQ M4PIUolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEGNUkHDNUwhVlGRMTygTG8uOSxiTWLQNkzDqGGwZF3SVFPDqGSxc3Wt[IVx\W6mZX70cJk> MV:yOFU2PjRzNR?=
Caco2 NWHNNoM2TnWwY4Tpc44hSXO|YYm= MWWzNE8yODEEoN88US=> NGPqWo8yPsLiaB?= NHLHZXBFVVOR NEPtfmli[3SrdnH0[ZMhVnKoMh?= M4rZ[VI1PTV4NEG1

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
VEGFR-1 / NRP-1 ; 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. 

p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min.

p-Src(Y418) / p-FAK(Y861) ; 

PubMed: 19383922     


Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ

18790786 19383922
Immunofluorescence
E-cadherin / Vimentin; 

PubMed: 30787271     


Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells.

ATXN2L / G3BP1; 

PubMed: 30787271     


Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules. 

30787271
Growth inhibition assay
Cell viability ; 

PubMed: 28339092     


Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations. 

28339092
In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
in solvent
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03784326 Not yet recruiting Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 31 2019 Early Phase 1
NCT03784326 Not yet recruiting Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 31 2019 Early Phase 1
NCT03626922 Not yet recruiting Metastatic Colorectal Cancer NSABP Foundation Inc|Merck Sharp & Dohme Corp.|Eli Lilly and Company April 2019 Phase 1
NCT03626922 Not yet recruiting Metastatic Colorectal Cancer NSABP Foundation Inc|Merck Sharp & Dohme Corp.|Eli Lilly and Company April 2019 Phase 1
NCT03366155 Recruiting Colorectal Cancer|Liver Metastases|Colorectal Adenocarcinoma|Colorectal Cancer With Hepatic Metastases|Colorectal Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 1 2019 Phase 2
NCT03813784 Not yet recruiting Gastric Cancer|GastroEsophageal Cancer Jiangsu HengRui Medicine Co. Ltd. March 2019 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID